BioAge reports positive phase 1 data for brain-penetrant drug BGE-102
Tweet Send to a Friend
BioAge Labs Inc. (NASDAQ: BIOA) announced interim results from its ongoing Phase 1 clinical trial of BGE-102, an oral drug ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
